Particle.news

Download on the App Store

Heston Blumenthal Warns Weight-Loss Drugs Threaten Fine-Dining Profits

Appetite suppression from GLP-1 treatments is expected to erode restaurant margins by shrinking demand for tasting menus.

Heston Blumenthal at his home in France
Image
Image

Overview

  • The chef told Times Radio that drugs like Wegovy, Ozempic and Mounjaro curb appetite, prompting diners to order smaller portions.
  • Blumenthal has lost 8 kg on Wegovy, which he began using to counteract weight gain from his bipolar disorder medication.
  • His Fat Duck Restaurant Group reported post-tax losses of £1.4 million in 2023 and £2.1 million in the year to May 2024.
  • He predicts the squeeze on portion sizes will deepen over the next six months and sees supermarkets and airlines feeling downstream effects.
  • Blumenthal cautioned that weight-loss injections may soon appear as over-the-counter patches or tablets, potentially accelerating appetite suppression.